Healthcare Economist in the Wall Street Journal


Loading ....
 

How do you measure the value of new drugs? An organization known as the Institute for Clinical and Economic Review relies almost exclusively on Quality-Adjusted Life Years (QALY)-based framework. While that is a good start, many new treatments may have impacts beyond directly on health including on educational outcomes, productivity, caregiver burden. Further, society is risk averse and values having treatments available in the case that they do become sick (“insurance value”). Limiting value assessment to only QALY-based models, “…risks mispricing innovative health therapies and disincentivizing investments in research and development.”

That is the key argument in my Letter to the Editor in the Wall Street Journal that was published last week. Do read the whole letter.

* This article was originally published here

 


RELATED PRODUCTS
  • How to Turn Your Passion Into A Business in 4 Simple Steps.
  • Get paid to write articles, blog posts, ebooks and many more.
  • The Best RSS Autoblog Tool For Blogger Blogspot Blog.
  • Discover how to boost your goal achieving skills in 30 days, guaranteed
  • Give Your Website, Blog or Product That Professional Touch
  • Find a plan that works for you and make that house, cabin, garage or workshop project.
  • Secrets Of Street Magic, Psychics, Bar Bets, Hypnosis, Nlp, Mystics And Fakirs And More
  • Stop fooling around with baby methods and beginner techniques.
  • The all in one email marketing and ebusiness automation system
  • Clickbank Ads
     

    Leave a Comment

    Az email címet nem tesszük közzé. A kötelező mezőket * karakterrel jelöltük